General Biologicals Corporation (TPEX:4117)

General Biologicals Revenue

General Biologicals had revenue of 155.22M TWD in the half year ending June 30, 2026, with 39.49% growth. This brings the company's total for the last twelve months to 260.23M, up 3.52% year-over-year. In the year 2025, General Biologicals had annual revenue of 215.74M, down -14.36%. That makes General Biologicals the 38,264th largest company in the world by revenue and 1,998th in Taiwan.

• Revenue (ttm): 260.23M
• Revenue Growth: +3.52%
• P/S Ratio: 2.08
• Revenue / Employee: 3.21M
• Employees: 81
• Market Cap: 541.56M

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Diagnostic Reagents 102.90M 44.6%
• Protein New Drug 54.68M 23.7%
• Medical Technology 43.51M 18.8%
• Lease Management 29.81M 12.9%

By Geography

Chart

• Taiwan 124.10M 57.5%
• North America 65.18M 30.2%
• Europe 21.35M 9.9%
• Asia (Excluding Taiwan) 3.91M 1.8%
• Other 1.20M 0.6%

Fiscal year ended Dec 31, 2025 See the full General Biologicals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	215.74M	-36.19M	-14.36%
Dec 31, 2024	251.93M	-12.90M	-4.87%
Dec 31, 2023	264.83M	-105.63M	-28.51%
Dec 31, 2022	370.46M	-181.20M	-32.85%
Dec 31, 2021	551.66M	75.79M	15.93%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 19, 2026

Data Sources Report a data error